title: Current trends in the use of liposomes for tumor targeting.
abstract: The use of liposomes for drug delivery began early in the history of pharmaceutical nanocarriers. These nanosized, lipid bilayered vesicles have become popular as drug delivery systems owing to their efficiency, biocompatibility, nonimmunogenicity, enhanced solubility of chemotherapeutic agents and their ability to encapsulate a wide array of drugs. Passive and ligand-mediated active targeting promote tumor specificity with diminished adverse off-target effects. The current field of liposomes focuses on both clinical and diagnostic applications. Recent efforts have concentrated on the development of multifunctional liposomes that target cells and cellular organelles with a single delivery system. This review discusses the recent advances in liposome research in tumor targeting.
authors.affiliation: Center for Pharmaceutical Biotechnology & Nanomedicine, 360 Huntington Avenue, 140 The Fenway, Northeastern University, Boston, MA 02115, USA.
authors.forename: Pranali P
authors.initials: PP
authors.lastname: Deshpande
authors.forename: Swati
authors.initials: S
authors.lastname: Biswas
authors.forename: Vladimir P
authors.initials: VP
authors.lastname: Torchilin
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016503:Drug Delivery Systems / Q000639:trends*; D004705:Endocytosis / Q000187:drug effects; D006801:Humans; D008081:Liposomes / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*; D013499:Surface Properties; D059016:Tumor Microenvironment / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D008081:Liposomes
references.citation: Mol Ther. 2011 Aug;19(8):1449-56
references.pmid: 21694702
references.citation: Bioconjug Chem. 2009 Jul;20(7):1332-9
references.pmid: 19601658
references.citation: ACS Nano. 2012 Apr 24;6(4):3491-8
references.pmid: 22409425
references.citation: Cancer. 2009 Aug 1;115(15):3475-82
references.pmid: 19536896
references.citation: Mini Rev Med Chem. 2011 Jan;11(1):1-17
references.pmid: 21235512
references.citation: Curr Opin Pharmacol. 2006 Oct;6(5):509-14
references.pmid: 16860608
references.citation: Nanomedicine. 2011 Dec;7(6):797-805
references.pmid: 21419872
references.citation: Int J Hyperthermia. 2011;27(2):156-71
references.pmid: 21158487
references.citation: Methods Mol Biol. 2010;605:1-27
references.pmid: 20072870
references.citation: Cancer Chemother Pharmacol. 2011 Oct;68(4):945-50
references.pmid: 21301848
references.citation: Ann Oncol. 2012 Apr;23(4):1030-6
references.pmid: 21693769
references.citation: Cancer Immunol Immunother. 2009 Mar;58(3):361-71
references.pmid: 18618109
references.citation: Int J Pharm. 2008 Aug 6;360(1-2):219-24
references.pmid: 18565703
references.citation: J Liposome Res. 2006;16(3):249-64
references.pmid: 16952879
references.citation: Bioconjug Chem. 2008 Aug;19(8):1588-95
references.pmid: 18627196
references.citation: Biochim Biophys Acta. 2008 Apr;1778(4):854-63
references.pmid: 18211818
references.citation: Nat Rev Cancer. 2002 Oct;2(10):750-63
references.pmid: 12360278
references.citation: Clin Transl Oncol. 2012 Feb;14(2):83-93
references.pmid: 22301396
references.citation: Curr Med Chem. 2012;19(31):5239-77
references.pmid: 22934774
references.citation: Adv Drug Deliv Rev. 2011 Mar 18;63(3):131-5
references.pmid: 20304019
references.citation: Anticancer Res. 2010 Feb;30(2):541-5
references.pmid: 20332467
references.citation: Nanotechnology. 2011 Dec 9;22(49):494011
references.pmid: 22101647
references.citation: Acc Chem Res. 2008 Jan;41(1):120-9
references.pmid: 17655275
references.citation: Colloids Surf B Biointerfaces. 2010 Mar 1;76(1):207-14
references.pmid: 19945258
references.citation: Cancer Chemother Pharmacol. 2013 Mar;71(3):555-64
references.pmid: 23212117
references.citation: Int J Hyperthermia. 2010;26(5):485-98
references.pmid: 20597627
references.citation: Drugs. 2007;67(15):2153-71
references.pmid: 17927282
references.citation: Acc Chem Res. 2013 Mar 19;46(3):792-801
references.pmid: 23387478
references.citation: Gynecol Oncol. 2006 Jun;101(3):423-8
references.pmid: 16325239
references.citation: Anticancer Drugs. 2011 Nov;22(10):949-62
references.pmid: 21970851
references.citation: J Control Release. 2008 Dec 8;132(2):113-23
references.pmid: 18796321
references.citation: Int J Pharm. 2007 Sep 5;342(1-2):194-200
references.pmid: 17583453
references.citation: AAPS J. 2007 May 11;9(2):E128-47
references.pmid: 17614355
references.citation: Mol Aspects Med. 2010 Feb;31(1):1-20
references.pmid: 19698742
references.citation: Anal Bioanal Chem. 2008 Aug;391(8):2717-27
references.pmid: 18351325
references.citation: Eur J Pharm Biopharm. 2009 Mar;71(3):431-44
references.pmid: 18977297
references.citation: FASEB J. 2010 Jun;24(6):1866-78
references.pmid: 20097877
references.citation: Biomed Pharmacother. 2009 Sep;63(8):603-7
references.pmid: 19019625
references.citation: Mol Pharm. 2012 Sep 4;9(9):2770-7
references.pmid: 22738645
references.citation: Int J Nanomedicine. 2007;2(3):277-88
references.pmid: 18019828
references.citation: Mol Pharm. 2012 Jul 2;9(7):2000-8
references.pmid: 22621404
references.citation: Int J Pharm. 2009 Jun 5;374(1-2):145-52
references.pmid: 19446771
references.citation: J Control Release. 2012 Jun 10;160(2):264-73
references.pmid: 22182771
references.citation: J Control Release. 2012 Jul 20;161(2):175-87
references.pmid: 21945285
references.citation: Integr Biol (Camb). 2013 Jan;5(1):96-107
references.pmid: 22869005
references.citation: Adv Drug Deliv Rev. 2006 Dec 1;58(14):1532-55
references.pmid: 17092599
references.citation: Handb Exp Pharmacol. 2010;(197):3-53
references.pmid: 20217525
references.citation: Pharm Res. 2012 Sep;29(9):2522-33
references.pmid: 22669705
references.citation: J Nanosci Nanotechnol. 2010 Aug;10(8):5129-36
references.pmid: 21125861
references.citation: Int J Nanomedicine. 2008;3(1):21-9
references.pmid: 18488413
references.citation: J Control Release. 2010 Aug 17;146(1):76-83
references.pmid: 20462513
references.citation: Urol Oncol. 2008 Jan-Feb;26(1):57-64
references.pmid: 18190833
references.citation: Expert Opin Drug Deliv. 2010 Dec;7(12):1329-41
references.pmid: 21118030
references.citation: Angew Chem Int Ed Engl. 2009;48(35):6494-8
references.pmid: 19623590
references.citation: Int J Pharm. 2009 Jan 21;366(1-2):201-10
references.pmid: 18835580
references.citation: Nano Lett. 2008 Aug;8(8):2559-63
references.pmid: 18611058
references.citation: J Pharm Pharmacol. 2009 Apr;61(4):445-9
references.pmid: 19298690
references.citation: J Microencapsul. 2011;28(3):220-7
references.pmid: 21425947
references.citation: PLoS One. 2012;7(7):e41410
references.pmid: 22844475
references.citation: Cancer Sci. 2011 Jul;102(7):1247-52
references.pmid: 21447010
references.citation: J Control Release. 2010 Dec 1;148(2):135-46
references.pmid: 20797419
references.citation: Biochim Biophys Acta. 2009 Apr;1793(4):746-54
references.pmid: 18948147
references.citation: J Clin Oncol. 2001 Mar 1;19(5):1444-54
references.pmid: 11230490
references.citation: Expert Opin Drug Deliv. 2013 Jan;10(1):73-87
references.pmid: 23199200
references.citation: J Control Release. 2012 May 10;159(3):393-402
references.pmid: 22286008
references.citation: Int J Nanomedicine. 2006;1(3):297-315
references.pmid: 17717971
references.citation: J Drug Target. 2011 Sep;19(8):606-14
references.pmid: 21275828
references.citation: AAPS J. 2012 Jun;14(2):303-15
references.pmid: 22415612
references.citation: J Control Release. 2012 Jan 30;157(2):279-86
references.pmid: 21871507
references.citation: J Control Release. 2012 Jul 20;161(2):317-27
references.pmid: 22565055
references.citation: Methods Enzymol. 2012;509:355-67
references.pmid: 22568915
references.citation: Appl Radiat Isot. 2009 Jul;67(7-8 Suppl):S109-10
references.pmid: 19395268
references.citation: Clin Cancer Res. 2012 Jan 15;18(2):454-64
references.pmid: 22065082
references.citation: Adv Drug Deliv Rev. 2008 Dec 14;60(15):1615-26
references.pmid: 18840489
references.citation: Int J Pharm. 2009 May 21;373(1-2):116-23
references.pmid: 19429296
references.citation: Biochim Biophys Acta. 2011 Dec;1816(2):232-46
references.pmid: 21840374
references.citation: Mol Pharm. 2011 Aug 1;8(4):1224-32
references.pmid: 21630705
references.citation: J Cell Mol Med. 2002 Oct-Dec;6(4):465-74
references.pmid: 12611636
references.citation: Int J Nanomedicine. 2012;7:3679-88
references.pmid: 22888227
references.citation: J Drug Deliv. 2013;2013:705265
references.pmid: 23533772
references.citation: Breast Cancer Res. 2002;4(3):95-9
references.pmid: 12052251
references.citation: Pharmacol Res. 2010 Aug;62(2):90-9
references.pmid: 20380880
references.citation: Int J Pharm. 2012 May 30;428(1-2):171-7
references.pmid: 22414425
references.citation: Acc Chem Res. 2011 Oct 18;44(10):1094-104
references.pmid: 21812415
references.citation: J Control Release. 2009 Jun 5;136(2):155-60
references.pmid: 19331844
references.citation: Chemother Res Pract. 2011;2011:125192
references.pmid: 22295201
references.citation: Expert Opin Drug Deliv. 2009 Aug;6(8):865-78
references.pmid: 19637974
references.citation: Nat Rev Cancer. 2008 Jun;8(6):473-80
references.pmid: 18469827
references.citation: Eur J Pharm Sci. 2000 Oct;11 Suppl 2:S81-91
references.pmid: 11033430
references.citation: J Control Release. 2012 Jun 10;160(2):117-34
references.pmid: 22484195
references.citation: Mol Ther. 2008 May;16(5):942-6
references.pmid: 18388916
references.citation: Int J Pharm. 2012 Aug 1;432(1-2):63-74
references.pmid: 22531856
references.citation: Expert Opin Drug Deliv. 2013 Apr;10(4):511-27
references.pmid: 23289519
references.citation: Int J Nanomedicine. 2011;6:1083-93
references.pmid: 21698075
references.citation: Cancer Biol Ther. 2012 Jan 1;13(1):50-60
references.pmid: 22336588
references.citation: Cancer Res. 2005 Dec 15;65(24):11631-8
references.pmid: 16357174
references.citation: Cancer Chemother Pharmacol. 1999;43(1):1-7
references.pmid: 9923534
references.citation: J Drug Target. 2011 Aug;19(7):552-61
references.pmid: 21348804
references.citation: Langmuir. 2011 Sep 6;27(17):10820-9
references.pmid: 21819046
references.citation: Ann Oncol. 2000 Jan;11(1):69-72
references.pmid: 10690390
references.citation: Int J Nanomedicine. 2011;6:3087-98
references.pmid: 22163162
references.citation: Proc Natl Acad Sci U S A. 1984 May;81(9):2752-6
references.pmid: 6585826
references.citation: J Drug Deliv. 2012;2012:581363
references.pmid: 21904682
references.citation: Cancer Chemother Pharmacol. 2002 Jul;50(1):6-8
references.pmid: 12111105
references.citation: J Drug Target. 2011 Jun;19(5):373-81
references.pmid: 20677917
references.citation: J Control Release. 2009 Feb 10;133(3):178-84
references.pmid: 18992290
references.citation: Mol Cancer Ther. 2007 Mar;6(3):844-55
references.pmid: 17339368
references.citation: J Pharm Sci. 2012 Jul;101(7):2468-78
references.pmid: 22517732
references.citation: Oncotarget. 2011 Apr;2(4):298-304
references.pmid: 21666286
references.citation: Int J Nanomedicine. 2012;7:3803-11
references.pmid: 22888235
references.citation: Future Oncol. 2011 Aug;7(8):937-45
references.pmid: 21823888
references.citation: J Biol Chem. 2009 May 8;284(19):12905-16
references.pmid: 19276080
references.citation: J Pharm Sci. 2005 May;94(5):1024-38
references.pmid: 15793796
references.citation: J Control Release. 2010 Jan 25;141(2):183-92
references.pmid: 19799948
references.citation: PLoS One. 2009 Oct 09;4(10):e7391
references.pmid: 19816581
references.citation: Int J Pharm. 2008 May 22;356(1-2):29-36
references.pmid: 18258394
references.citation: Methods Mol Biol. 2010;624:249-65
references.pmid: 20217601
references.citation: Tumour Biol. 2012 Jun;33(3):661-7
references.pmid: 22302484
references.citation: J Drug Deliv. 2011;2011:939851
references.pmid: 21490759
references.citation: Methods Mol Biol. 2010;605:213-42
references.pmid: 20072884
references.citation: Int J Nanomedicine. 2012;7:739-51
references.pmid: 22359453
references.citation: J Control Release. 2012 Dec 10;164(2):138-44
references.pmid: 22595146
references.citation: Cancer Lett. 2013 Jul 1;334(2):293-301
references.pmid: 22743614
references.citation: Expert Opin Drug Deliv. 2011 May;8(5):565-80
references.pmid: 21492058
references.citation: Nano Lett. 2010 Jul 14;10(7):2484-92
references.pmid: 20515041
references.citation: Adv Drug Deliv Rev. 2013 Jan;65(1):71-9
references.pmid: 23088862
references.citation: Eur J Pharm Biopharm. 2013 Aug;84(3):517-25
references.pmid: 23333899
references.citation: Anticancer Res. 2005 Jan-Feb;25(1A):331-41
references.pmid: 15816556
references.citation: Eur J Pharm Biopharm. 2012 Feb;80(2):241-6
references.pmid: 21888972
references.citation: Anal Bioanal Chem. 2010 Nov;398(6):2645-54
references.pmid: 20596697
references.citation: Anticancer Res. 2011 May;31(5):1521-5
references.pmid: 21617205
references.citation: Cancer Treat Rev. 2008 Nov;34(7):592-602
references.pmid: 18538481
references.citation: Chem Commun (Camb). 2010 Jan 14;46(2):249-51
references.pmid: 20024341
references.citation: Int J Pharm. 2012 Feb 28;423(2):365-77
references.pmid: 22209825
references.citation: Nat Rev Drug Discov. 2005 Feb;4(2):145-60
references.pmid: 15688077